This book uniquely summarizes approaches to developing dermatological drugs in a regulated environment from the perspective of the pharmaceutical industry. It brings together the insights of skilled and experienced industry experts to reveal the complexities of dermatological drug development, covering topical, oral, and biologic drugs. This book fills an important gap, as there is currently no other textbook addressing dermatological drug development, explaining and illustrating why unique nonclinical and clinical studies are necessary and how they are typically designed and conducted. The drug development process is also an evolving strategy that is characterized by communicating, negotiating, and agreeing with regulatory agencies, such as FDA (US), EMA (EU), and PMDA (Japan).

Drug repurposing or drug repositioning is a new approach to presenting new indications for common commercial and clinically approved existing drugs. For example, chloroquine, an old antimalarial drug, showed promising results for treating COVID-19, interfering with MDR in several types of cancer, and chemosensitizing human leukemic cells.This book focuses on the hypothesis, risk/benefits, and economic impacts of drug repurposing on drug discovery in dermatology, infectious diseases, neurological disorders, cancer, and orphan diseases. It brings together up-to-date research to provide readers with an informative, illustrative, and easy-to-read book useful for students, clinicians, and the pharmaceutical industry.

Evidence-based Dermatology, Second Edition is aunique book in the field of clinical dermatology. Written andedited by some of the world’s leading experts inevidence-based dermatology, it takes a highly evidence-basedapproach to the treatment of all major and many of the less commonskin conditions. The toolbox at the beginning of the book explaining how tocritically appraise different studies, along with the comprehensivereviewing and appraisal of evidence in the clinical chapters makesthis book distinctive in its field as do the treatmentrecommendations which are based on the discussion of the bestavailable evidence using a question-driven approach and a commonstructure on dealing with efficacy, drawbacks and implications forclinical practice.

Designed with practical usability in mind, Comprehensive Dermatologic Drug Therapy, 4th Edition, helps you safely and effectively treat the skin disorders you're likely to see in your practice. Dr. Stephen E. Wolverton and new associate editor Dr. Jashin J. Wu lead a team of global experts to bring you concise, complete guidance on today's full spectrum of topical, intralesional, and systemic drugs. You'll prescribe with confidence thanks to expert coverage of which drugs to use, when to use them, and adverse effects to monitor. - Includes new drug interaction tables, drug risk profiles, and FDA guidelines, as well as two new appendices that summarize chapter questions and summarize highest-risk drug interactions. - Covers the best uses for new biologic therapeutics. - Contains new chapters covering medical decision-making principles, PDE-4 and JAK inhibitors, interleukin 17 inhibitors, interleukin 23 inhibitors, additional biologic therapeutics, and hedgehog pathway inhibitors. - Contains quick-access summaries of indications/contraindications, dosage guidelines, drug interactions, drug monitoring guidelines, adverse effects, and treatment protocols. - Features a highly detailed, disease-specific index, as well as purchase information for major drugs. - Helps you assess your knowledge and prepare for certification or recertification with about 800 review questions and answers throughout the book. - Enhanced eBook version included with purchase. Your enhanced eBook allows you to access all of the text, figures, and references from the book on a variety of devices.

With the continued advancement of better-quality control and patient outcome reporting systems, changes in the development, control, and regulation of all pharmaceutical delivery systems including transdermal and topical products have been happening on a continuous basis. In light of various quality issues that have been reported by patients and practitioners resulting in the recall or removal of products from the market, both the pharmaceutical industries and regulatory agencies have been adopting new measures to address these issues. With chapters written by experts in this field, this book takes a 21st century multidisciplinary and cross-functional look at these dosage forms to improve the development, design, manufacturing, quality, clinical performance, safety, and regulation of these products. This book offers a wealth of up-to-date information organized in a logical sequence corresponding to various stages of research, development, and commercialization of dermal drug delivery products. The authors have been carefully selected from different sectors of pharmaceutical science for their expertise in their selected areas to present objectively a balanced view of the current state of these products development and commercialization via regulatory approval. Their insights will provide useful information to others to ensure the successful development of the next generation dermal drug products. Key Features: Presents current advancements including new technologies of transdermal and topical dosage forms. Presents challenges in the development of the new generation of transdermal and topical dosage forms. Introduces new technologies and QbD (quality by design) aspects of manufacturing and control strategies. Includes new perspectives on pre-clinical and clinical development, regulatory considerations, safety and quality. Discusses regulatory challenges, gaps, and future considerations for dermal drug delivery systems.

Pain is both a symptom and a disease. It manifests in multiple forms and its treatment is complex. Physical, social, economic, and emotional consequences of pain can impair an individual's overall health, well-being, productivity, and relationships in myriad ways. The impact of pain at a population level is vast and, while estimates differ, the Centers for Disease Control and Prevention reported that 50 million U.S. adults are living in pain. In terms of pain's global impact, estimates suggest the problem affects approximately 1 in 5 adults across the world, with nearly 1 in 10 adults newly diagnosed with chronic pain each year. In recent years, the issues surrounding the complexity of pain management have contributed to increased demand for alternative strategies for treating pain. One such strategy is to expand use of topical pain medicationsâ€"medications applied to intact skin. This nonoral route of administration for pain medication has the potential benefit, in theory, of local activity and fewer systemic side effects. Compounding is an age-old pharmaceutical practice of combining, mixing, or adjusting ingredients to create a tailored medication to meet the needs of a patient. The aim of compounding, historically, has been to provide patients with access to therapeutic alternatives that are safe and effective, especially for people with clinical needs that cannot otherwise be met by commercially available FDA-approved drugs. Compounded Topical Pain Creams explores issues regarding the safety and effectiveness of the ingredients in these pain creams. This report analyzes the available scientific data relating to the ingredients used in compounded topical pain creams and offers recommendations regarding the treatment of patients.

This lavishly illustrated guide from experts will enable practitioners to get the most out of dermoscopy for investigations and treatments in general dermatology.

Recent advances in our understanding of the development and morphology of normal skin have led to improved methods to deliver therapeutic compounds to targeted areas both within the skin and systemically. This reference provides a clear overview of pharmaceutical and cosmetic practices, drugs, and therapies to manage and treat major and minor skin disorders. It examines the efficiency and delivery of topical therapies and explains how percutaneous absorption is affected by age, skin, site, race, skin disease, and damage and product form. Particular emphasis is on novel treatment approaches for major skin diseases and injuries pertaining to wounds and burns.

Nanoscience in Dermatology covers one of the two fastest growing areas within dermatological science, nanoscience and nanotechnology in dermatology. Recently, great progress has been made in the research and development of nanotechnologies and nanomaterials related to various applications in medicine and, in general, the life sciences. There is increasing enthusiasm for nanotechnology applications in dermatology (drug delivery, diagnostics, therapeutics, imaging, sensors, etc.) for understanding skin biology, improving early detection and treatment of skin diseases, and in the design and optimization of cosmetics. Light sensitive nanoparticles have recently been explored, opening a new era for the combined applications of light with nanotechnology, also called photonanodermatology. However, concerns have been raised regarding the adverse effects of intentional and unintentional nanoparticle exposure and their toxicity. Written by experts working in these exciting fields, this book extensively covers nanotechnology applications, together with the fundamentals and toxicity aspects. It not only addresses current applications of nanotechnology, but also discusses future trends of these ever-growing and rapidly changing fields, providing scientists and dermatologists with a clear understanding of the advantages and challenges of nanotechnology in skin medicine. - Provides knowledge of current and future applications of nanoscience and nanotechnology in dermatology - Outlines the fundamentals, methods, toxicity aspects, and other relevant aspects for nanotechnology based applications in dermatology - Coherently structured book written by experts working in the fields covered

The skin is the largest human organ system. Loss of skin integrity due to injury or illness results in a substantial physiologic imbalance and ultimately in severe disability or death. From burn victims to surgical scars and plastic surgery, the therapies resulting from skin tissue engineering and regenerative medicine are important to a broad spectrum of patients. Skin Tissue Engineering and Regenerative Medicine provides a translational link for biomedical researchers across fields to understand the inter-disciplinary approaches which expanded available therapies for patients and additional research collaboration. This work expands on the primary literature on the state of the art of cell therapies and biomaterials to review the most widely used surgical therapies for the specific clinical scenarios. - Explores cellular and molecular processes of wound healing, scar formation, and dermal repair - Includes examples of animal models for wound healing and translation to the clinical world - Presents the current state of, and clinical opportunities for, extracellular matrices, natural biomaterials, synthetic biomaterials, biologic skin substitutes, and adult and fetal stem and skin cells for skin regenerative therapies and wound management - Discusses new innovative approaches for wound healing including skin bioprinting and directed cellular therapies